Yoon Joonho, Lee Jong In, Baik Soon Koo, Lee Kwang Ho, Sohn Joon Hyung, Lee Hyean Woo, Namkung Jun, Chang Sei Jin, Choi Jong Whan, Kim Hyun Won, Yeh Byung-Il
Department of Biochemistry and Institute of Basic Medical Sciences, Wonju College of Medicine, Yonsei University, 162 Ilsandong, Wonju, Gangwondo 220-701, Republic of Korea.
World J Gastroenterol. 2007 Dec 14;13(46):6236-42. doi: 10.3748/wjg.v13.i46.6236.
To confirm the predictive factors for interferon (IFN)-alpha and ribavirin combination therapy for chronic hepatitis patients with hepatitis C virus (HCV) genotype 1b.
HCV RNA from 50 patients infected with HCV genotype 1b was studied by cloning and sequencing of interferon sensitivity determining region (ISDR), PKR-eIF2alpha phosphorylation homology domain (PePHD). Patients were treated with IFN-alpha and ribavirin for 6 mo and grouped by effectiveness of the therapy. A variety of factors were analyzed.
Our data showed that age, HCV RNA titer, and ISDR type could be used as the predictive factors for combined IFN-alpha and ribavirin efficacy. Characteristically, mutations in PePHD appeared only when the combination therapy was effective. Other factors, such as sex and alanine aminotransferase (ALT) level, were not related to its efficacy. Adjusting for age and HCV RNA titer indicated that the ISDR type was the most potent predictive factor.
HCV RNA ISDR type is an important factor for predicting efficacy of IFN-alpha and ribavirin combination therapy in Korean patients.
确定干扰素(IFN)-α与利巴韦林联合治疗丙型肝炎病毒(HCV)基因1b型慢性肝炎患者的预测因素。
通过干扰素敏感性决定区(ISDR)、PKR-eIF2α磷酸化同源结构域(PePHD)的克隆和测序,研究50例感染HCV基因1b型患者的HCV RNA。患者接受IFN-α和利巴韦林治疗6个月,并根据治疗效果分组。分析了多种因素。
我们的数据表明,年龄、HCV RNA滴度和ISDR类型可作为IFN-α与利巴韦林联合疗效的预测因素。特征性地,仅在联合治疗有效时PePHD中才出现突变。其他因素,如性别和丙氨酸转氨酶(ALT)水平,与其疗效无关。校正年龄和HCV RNA滴度后表明,ISDR类型是最有效的预测因素。
HCV RNA ISDR类型是预测韩国患者IFN-α与利巴韦林联合治疗疗效的重要因素。